Concepts (298)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 29 | 2023 | 711 | 5.930 |
Why?
|
| Pharmacy Service, Hospital | 13 | 2023 | 52 | 3.220 |
Why?
|
| Pharmacists | 13 | 2023 | 125 | 2.780 |
Why?
|
| Emergency Medical Services | 7 | 2021 | 225 | 2.480 |
Why?
|
| Antivenins | 5 | 2017 | 12 | 1.740 |
Why?
|
| Medication Errors | 5 | 2020 | 116 | 1.690 |
Why?
|
| Status Epilepticus | 3 | 2023 | 74 | 1.590 |
Why?
|
| Hypotension | 2 | 2021 | 74 | 1.500 |
Why?
|
| Snake Bites | 4 | 2017 | 7 | 1.450 |
Why?
|
| Insulin | 3 | 2020 | 619 | 1.380 |
Why?
|
| Hypoglycemia | 2 | 2021 | 72 | 1.370 |
Why?
|
| Emergency Medicine | 3 | 2023 | 88 | 1.370 |
Why?
|
| Immunoglobulin Fragments | 4 | 2017 | 14 | 1.370 |
Why?
|
| Disaster Planning | 3 | 2014 | 105 | 1.300 |
Why?
|
| Patient Discharge | 2 | 2022 | 294 | 1.280 |
Why?
|
| Emergency Treatment | 4 | 2015 | 52 | 1.280 |
Why?
|
| Students, Pharmacy | 4 | 2021 | 79 | 1.210 |
Why?
|
| Humans | 76 | 2023 | 68618 | 1.200 |
Why?
|
| Retrospective Studies | 23 | 2022 | 7277 | 1.090 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 1026 | 1.070 |
Why?
|
| Anticonvulsants | 5 | 2023 | 223 | 1.050 |
Why?
|
| Hemorrhage | 3 | 2019 | 328 | 1.040 |
Why?
|
| Hyperglycemia | 2 | 2020 | 158 | 1.030 |
Why?
|
| Epinephrine | 3 | 2021 | 103 | 0.990 |
Why?
|
| Bioterrorism | 2 | 2014 | 12 | 0.970 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2021 | 18 | 0.960 |
Why?
|
| Hypnotics and Sedatives | 4 | 2021 | 96 | 0.960 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2022 | 45 | 0.950 |
Why?
|
| Benzodiazepines | 3 | 2023 | 130 | 0.940 |
Why?
|
| Blood Glucose | 4 | 2021 | 631 | 0.920 |
Why?
|
| Pharmacy | 2 | 2023 | 26 | 0.910 |
Why?
|
| Drug Prescriptions | 3 | 2022 | 135 | 0.900 |
Why?
|
| Professional Role | 4 | 2020 | 80 | 0.890 |
Why?
|
| Rabies | 2 | 2013 | 5 | 0.880 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 249 | 0.870 |
Why?
|
| Internship, Nonmedical | 4 | 2012 | 19 | 0.840 |
Why?
|
| Emergency Nursing | 2 | 2014 | 9 | 0.800 |
Why?
|
| Calcium Channel Blockers | 3 | 2020 | 138 | 0.790 |
Why?
|
| Sympathomimetics | 1 | 2021 | 16 | 0.780 |
Why?
|
| Critical Illness | 4 | 2013 | 191 | 0.780 |
Why?
|
| Propofol | 1 | 2021 | 36 | 0.770 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 148 | 0.770 |
Why?
|
| Tramadol | 1 | 2021 | 3 | 0.770 |
Why?
|
| Dantrolene | 1 | 2021 | 8 | 0.760 |
Why?
|
| Pharmacy Residencies | 1 | 2021 | 18 | 0.760 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 13 | 0.760 |
Why?
|
| Malignant Hyperthermia | 1 | 2021 | 10 | 0.760 |
Why?
|
| Doxycycline | 1 | 2021 | 49 | 0.750 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 504 | 0.750 |
Why?
|
| Acetylcysteine | 3 | 2022 | 296 | 0.750 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 362 | 0.720 |
Why?
|
| Hypothermia, Induced | 2 | 2011 | 93 | 0.720 |
Why?
|
| Drug Overdose | 1 | 2021 | 67 | 0.720 |
Why?
|
| Diltiazem | 1 | 2019 | 26 | 0.690 |
Why?
|
| Hyperkalemia | 1 | 2019 | 21 | 0.680 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 166 | 0.680 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2010 | 61 | 0.650 |
Why?
|
| Heart Arrest | 2 | 2011 | 113 | 0.630 |
Why?
|
| Adrenal Insufficiency | 2 | 2008 | 10 | 0.630 |
Why?
|
| Crotalid Venoms | 3 | 2017 | 6 | 0.610 |
Why?
|
| Ketamine | 2 | 2017 | 57 | 0.600 |
Why?
|
| Urinary Tract Infections | 1 | 2018 | 71 | 0.600 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 63 | 0.590 |
Why?
|
| Body Weight | 1 | 2019 | 554 | 0.590 |
Why?
|
| Antiemetics | 1 | 2017 | 8 | 0.580 |
Why?
|
| Delirium | 1 | 2017 | 45 | 0.580 |
Why?
|
| Nausea | 1 | 2017 | 47 | 0.570 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 45 | 0.570 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2017 | 8 | 0.570 |
Why?
|
| Vomiting | 1 | 2017 | 56 | 0.560 |
Why?
|
| Pregnancy, Ectopic | 1 | 2017 | 16 | 0.560 |
Why?
|
| Clinical Protocols | 3 | 2012 | 172 | 0.550 |
Why?
|
| Methotrexate | 1 | 2017 | 91 | 0.550 |
Why?
|
| Glucagon | 2 | 2016 | 22 | 0.550 |
Why?
|
| Acetaminophen | 3 | 2022 | 111 | 0.550 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 122 | 0.540 |
Why?
|
| Acute Disease | 6 | 2019 | 658 | 0.530 |
Why?
|
| Ambulatory Care | 1 | 2018 | 340 | 0.530 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 49 | 0.530 |
Why?
|
| Foreign Bodies | 2 | 2016 | 58 | 0.520 |
Why?
|
| Administration, Intravenous | 3 | 2020 | 89 | 0.520 |
Why?
|
| Internship and Residency | 1 | 2021 | 596 | 0.510 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2014 | 1 | 0.490 |
Why?
|
| Smallpox | 1 | 2014 | 1 | 0.490 |
Why?
|
| Botulism | 1 | 2014 | 4 | 0.490 |
Why?
|
| Esophagus | 2 | 2016 | 303 | 0.480 |
Why?
|
| Chemical Warfare Agents | 1 | 2014 | 4 | 0.470 |
Why?
|
| Organophosphate Poisoning | 1 | 2014 | 6 | 0.460 |
Why?
|
| Middle Aged | 16 | 2021 | 21147 | 0.460 |
Why?
|
| Tranexamic Acid | 1 | 2014 | 37 | 0.460 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 1745 | 0.450 |
Why?
|
| Fibrinolytic Agents | 3 | 2016 | 377 | 0.450 |
Why?
|
| Antifibrinolytic Agents | 1 | 2014 | 52 | 0.450 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2016 | 296 | 0.450 |
Why?
|
| Rabies Vaccines | 1 | 2013 | 4 | 0.440 |
Why?
|
| Vasospasm, Intracranial | 2 | 2010 | 16 | 0.430 |
Why?
|
| Bacteria | 1 | 2014 | 193 | 0.430 |
Why?
|
| Immunoglobulins | 1 | 2013 | 97 | 0.420 |
Why?
|
| Male | 21 | 2021 | 37321 | 0.420 |
Why?
|
| Stroke | 5 | 2016 | 2163 | 0.410 |
Why?
|
| Dexmedetomidine | 2 | 2017 | 13 | 0.400 |
Why?
|
| Neurosurgery | 2 | 2009 | 42 | 0.400 |
Why?
|
| Analgesia | 2 | 2015 | 58 | 0.390 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2013 | 42 | 0.390 |
Why?
|
| Nurse Practitioners | 1 | 2012 | 90 | 0.380 |
Why?
|
| Education, Continuing | 4 | 2014 | 28 | 0.370 |
Why?
|
| Shivering | 1 | 2010 | 1 | 0.370 |
Why?
|
| Meperidine | 1 | 2010 | 5 | 0.370 |
Why?
|
| Sepsis | 2 | 2012 | 233 | 0.370 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 334 | 0.360 |
Why?
|
| Clonidine | 1 | 2010 | 66 | 0.360 |
Why?
|
| Antidotes | 4 | 2017 | 21 | 0.360 |
Why?
|
| Immunoglobulin Fab Fragments | 4 | 2017 | 48 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 106 | 0.360 |
Why?
|
| Analgesics | 1 | 2011 | 118 | 0.360 |
Why?
|
| Treatment Outcome | 11 | 2019 | 7029 | 0.350 |
Why?
|
| Ethylene Glycol | 1 | 2009 | 4 | 0.340 |
Why?
|
| Methanol | 1 | 2009 | 9 | 0.340 |
Why?
|
| Female | 18 | 2021 | 38074 | 0.340 |
Why?
|
| Cervical Vertebrae | 2 | 2008 | 86 | 0.340 |
Why?
|
| Incidence | 3 | 2021 | 1603 | 0.340 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 212 | 0.330 |
Why?
|
| Insulin Infusion Systems | 1 | 2009 | 27 | 0.330 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 438 | 0.320 |
Why?
|
| Adult | 14 | 2021 | 21403 | 0.320 |
Why?
|
| Neck Injuries | 1 | 2008 | 17 | 0.310 |
Why?
|
| Spinal Cord Injuries | 3 | 2010 | 551 | 0.300 |
Why?
|
| Aged | 10 | 2021 | 14862 | 0.300 |
Why?
|
| Length of Stay | 4 | 2020 | 780 | 0.300 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2007 | 8 | 0.290 |
Why?
|
| Aminophylline | 1 | 2007 | 2 | 0.290 |
Why?
|
| United States | 8 | 2017 | 7367 | 0.280 |
Why?
|
| Bradycardia | 1 | 2007 | 45 | 0.280 |
Why?
|
| Anticoagulants | 2 | 2020 | 356 | 0.280 |
Why?
|
| Spinal Injuries | 1 | 2007 | 30 | 0.280 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 71 | 0.280 |
Why?
|
| Blood Loss, Surgical | 1 | 2006 | 79 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 130 | 0.260 |
Why?
|
| Ubiquinone | 1 | 2005 | 14 | 0.260 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 218 | 0.260 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 234 | 0.260 |
Why?
|
| Hospitals, University | 3 | 2010 | 169 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2012 | 504 | 0.240 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2006 | 373 | 0.240 |
Why?
|
| Patient Care Team | 3 | 2011 | 311 | 0.230 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2021 | 98 | 0.230 |
Why?
|
| Intubation, Intratracheal | 2 | 2015 | 99 | 0.220 |
Why?
|
| Conscious Sedation | 2 | 2021 | 61 | 0.220 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 102 | 0.220 |
Why?
|
| Antioxidants | 1 | 2005 | 304 | 0.220 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 848 | 0.210 |
Why?
|
| Poisoning | 2 | 2015 | 21 | 0.210 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 5 | 0.210 |
Why?
|
| Procainamide | 1 | 2021 | 12 | 0.190 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 62 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 498 | 0.180 |
Why?
|
| Seizures | 1 | 2023 | 279 | 0.180 |
Why?
|
| Free Radical Scavengers | 1 | 2021 | 112 | 0.180 |
Why?
|
| Kentucky | 2 | 2012 | 13 | 0.170 |
Why?
|
| Methylprednisolone | 2 | 2010 | 99 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 131 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2016 | 186 | 0.170 |
Why?
|
| Blood Coagulation Factors | 1 | 2019 | 44 | 0.170 |
Why?
|
| Algorithms | 2 | 2017 | 1196 | 0.170 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 43 | 0.170 |
Why?
|
| Potassium | 1 | 2019 | 168 | 0.160 |
Why?
|
| Intensive Care Units | 3 | 2015 | 344 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 274 | 0.160 |
Why?
|
| Glucose | 1 | 2019 | 307 | 0.150 |
Why?
|
| Infusions, Intravenous | 3 | 2021 | 334 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 567 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1140 | 0.150 |
Why?
|
| Heart Rate | 1 | 2019 | 568 | 0.150 |
Why?
|
| Crotalus | 1 | 2017 | 4 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2017 | 128 | 0.140 |
Why?
|
| Hospital Mortality | 2 | 2009 | 384 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3259 | 0.140 |
Why?
|
| Time Factors | 3 | 2017 | 4655 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2016 | 665 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 88 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2023 | 3705 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 772 | 0.140 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2016 | 19 | 0.140 |
Why?
|
| Heart Failure | 1 | 2005 | 1180 | 0.140 |
Why?
|
| Angioedemas, Hereditary | 1 | 2016 | 26 | 0.130 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 51 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 117 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1553 | 0.130 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2015 | 18 | 0.130 |
Why?
|
| Androstanols | 1 | 2015 | 7 | 0.130 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2015 | 11 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 1451 | 0.130 |
Why?
|
| Succinylcholine | 1 | 2015 | 15 | 0.130 |
Why?
|
| Hypertension | 1 | 2004 | 1535 | 0.130 |
Why?
|
| Education, Pharmacy | 2 | 2007 | 102 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 1851 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 233 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2016 | 714 | 0.120 |
Why?
|
| Recurrence | 1 | 2017 | 948 | 0.120 |
Why?
|
| Organophosphates | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1076 | 0.110 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2013 | 1 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2012 | 383 | 0.110 |
Why?
|
| Disease Vectors | 1 | 2013 | 8 | 0.110 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Child | 2 | 2022 | 6405 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2800 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2016 | 400 | 0.110 |
Why?
|
| Risk Factors | 2 | 2021 | 5731 | 0.110 |
Why?
|
| Empirical Research | 1 | 2012 | 12 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 592 | 0.100 |
Why?
|
| Esophageal Stenosis | 1 | 2012 | 36 | 0.100 |
Why?
|
| Drug Utilization Review | 1 | 2012 | 19 | 0.100 |
Why?
|
| Saliva | 1 | 2013 | 142 | 0.100 |
Why?
|
| Food | 1 | 2012 | 52 | 0.100 |
Why?
|
| Shock | 1 | 2012 | 28 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 215 | 0.100 |
Why?
|
| Electrolytes | 1 | 2011 | 47 | 0.100 |
Why?
|
| Pneumonia | 1 | 2012 | 110 | 0.100 |
Why?
|
| Drug Therapy | 1 | 2011 | 71 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 1 | 2012 | 107 | 0.100 |
Why?
|
| Young Adult | 3 | 2017 | 5717 | 0.090 |
Why?
|
| Pregnancy | 1 | 2017 | 2334 | 0.090 |
Why?
|
| Education, Nursing | 1 | 2011 | 55 | 0.090 |
Why?
|
| Neoplasms | 1 | 2022 | 1667 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 271 | 0.090 |
Why?
|
| Cross Infection | 1 | 2012 | 195 | 0.090 |
Why?
|
| Neuroprotective Agents | 2 | 2010 | 317 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 4848 | 0.090 |
Why?
|
| Nimodipine | 1 | 2010 | 5 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 281 | 0.090 |
Why?
|
| Body Temperature | 1 | 2010 | 116 | 0.090 |
Why?
|
| Critical Care | 1 | 2012 | 263 | 0.090 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 87 | 0.080 |
Why?
|
| Cosyntropin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Suicide, Attempted | 1 | 2009 | 72 | 0.080 |
Why?
|
| Intracranial Pressure | 1 | 2008 | 58 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2009 | 174 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2009 | 190 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 219 | 0.080 |
Why?
|
| Animals | 2 | 2017 | 20881 | 0.070 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2008 | 291 | 0.070 |
Why?
|
| Adenosine Diphosphate | 1 | 2006 | 66 | 0.070 |
Why?
|
| Coronary Thrombosis | 1 | 2006 | 45 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2006 | 80 | 0.070 |
Why?
|
| Inservice Training | 1 | 2006 | 68 | 0.070 |
Why?
|
| Coenzymes | 1 | 2005 | 3 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2007 | 230 | 0.060 |
Why?
|
| Bacteremia | 1 | 2007 | 155 | 0.060 |
Why?
|
| Aspirin | 1 | 2006 | 295 | 0.060 |
Why?
|
| Research | 1 | 2006 | 214 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 1426 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 694 | 0.050 |
Why?
|
| Respiration, Artificial | 2 | 2015 | 190 | 0.050 |
Why?
|
| Ventricular Remodeling | 1 | 2005 | 318 | 0.050 |
Why?
|
| Emergencies | 1 | 2022 | 107 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 135 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2005 | 718 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 132 | 0.050 |
Why?
|
| Sodium Channel Blockers | 1 | 2020 | 23 | 0.050 |
Why?
|
| Factor Xa | 1 | 2019 | 10 | 0.040 |
Why?
|
| Hemostasis | 1 | 2019 | 32 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 130 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 2007 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2020 | 601 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 742 | 0.040 |
Why?
|
| Hydromorphone | 1 | 2017 | 14 | 0.040 |
Why?
|
| Anesthetics, Dissociative | 1 | 2017 | 11 | 0.040 |
Why?
|
| Flumazenil | 1 | 2017 | 23 | 0.040 |
Why?
|
| Naloxone | 1 | 2017 | 56 | 0.040 |
Why?
|
| Fentanyl | 1 | 2017 | 26 | 0.040 |
Why?
|
| Lorazepam | 1 | 2017 | 54 | 0.040 |
Why?
|
| Midazolam | 1 | 2017 | 46 | 0.040 |
Why?
|
| Haloperidol | 1 | 2017 | 95 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2004 | 1615 | 0.040 |
Why?
|
| Narcotics | 1 | 2017 | 65 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2016 | 22 | 0.030 |
Why?
|
| Plasma | 1 | 2016 | 58 | 0.030 |
Why?
|
| Narcotic Antagonists | 1 | 2017 | 184 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 247 | 0.030 |
Why?
|
| Drug Information Services | 1 | 2012 | 10 | 0.030 |
Why?
|
| Piracetam | 1 | 2012 | 10 | 0.030 |
Why?
|
| Phenytoin | 1 | 2012 | 27 | 0.030 |
Why?
|
| Endoscopy | 1 | 2016 | 464 | 0.030 |
Why?
|
| Resuscitation | 1 | 2012 | 77 | 0.030 |
Why?
|
| Catecholamines | 1 | 2012 | 73 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2012 | 59 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 425 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 202 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1046 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3187 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 807 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1619 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.010 |
Why?
|